Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Metastatic melanoma is often resistant to current therapies, necessitating the discovery of novel treatment strategies.
• There is a critical need for effective therapeutic agents to combat chemoresistant melanoma.
• Identifying compounds with melanoma-specific cytotoxicity is essential for developing new treatments.

Purpose of the Study:

• To screen a library of compounds for novel agents effective against chemoresistant melanoma.
• To identify compounds that inhibit melanoma cell growth while sparing normal melanocytes.
• To investigate the mechanism of action of promising candidate drugs, particularly mebendazole.

Main Methods:

• Screening of 2,000 compounds from the Spectrum Library against chemoresistant melanoma cell lines (M-14, SK-Mel-19) and a normal melanocyte cell line (melan-a).
• Prioritization of mebendazole for further mechanistic studies based on its efficacy and pharmacokinetic profile.
• Characterization of mebendazole's mechanism of action, including IC(50) determination and analysis of apoptosis induction via Bcl-2 and Bax pathways.

Main Results:

• Ten compounds inhibited melanoma cell growth with minimal toxicity to melanocytes.
• Four benzimidazole compounds, including mebendazole, were identified as potent inhibitors.
• Mebendazole demonstrated significant melanoma growth inhibition (average IC(50) of 0.32 micromol/L) and preferentially induced apoptosis in melanoma cells.
• Mebendazole-induced apoptosis is mediated by Bcl-2 phosphorylation, preventing its interaction with Bax.

Conclusions:

• The compound screening approach successfully identified potent agents against chemoresistant melanoma.
• Mebendazole is a potent, melanoma-specific cytotoxic agent with a promising mechanism of action.
• Targeting Bcl-2 phosphorylation is crucial for mebendazole's efficacy in melanoma treatment.